As GnRH antagonists do not provoke a testosterone flare-up phenomenon and that testosterone surges during maintenance with GnRH agonists are also avoided, they present an excellent treatment option in patients with symptomatic prostate cancer, especially those who present with bone pain, ureteric or BOO, bone fractures or spinal cord compression [4]. Here, GNRH1 is linked to prostate carcinoma.